Akoustis Technologies Inc reports results for the quarter ended in December - Earnings Summary

Aktis Oncology

07/02/2023 14:32

* Akoustis Technologies Inc  AKTS.OQ  reported a quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 25 cents per share.
    * Revenue rose 59.7% to $5.87 million from a year ago;
analysts
expected $5.92 million. 
    * Akoustis Technologies Inc's reported EPS for the quarter
was a
loss of 19 cents​.
    * The mean earnings estimate of analysts had fallen by
about 28.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Akoustis Technologies Inc shares had risen by 58.5% this
quarter.
    * The company reported a quarterly loss of $11.16 million.
    * Wall Street's median 12-month price target for Akoustis
Technologies Inc is $7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
7 at 02:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.25          -0.19          Beat
 Sep. 30 2022      -0.20          -0.28          Missed
 Jun. 30 2022      -0.19          -0.26          Missed
 Mar. 31 2022      -0.22          -0.22          Met